NCT03088852 is a Phase 4 clinical trial of Magnesium Citrate 100 MG in Hypomagnesemia, sponsored by Frieda Wolf.

Who is sponsoring NCT03088852?

NCT03088852 is sponsored by Frieda Wolf.

What drugs are being tested in NCT03088852?

Interventions in NCT03088852: Magnesium Citrate 100 MG.

What condition does NCT03088852 study?

NCT03088852 studies Hypomagnesemia.

Is NCT03088852 still recruiting?

NCT03088852 is currently recruiting now. Last updated 16 March 2025.

Last reviewed 2025-03-16 · How we verify

NCT03088852

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Magnesium Deficiency In Patients Hospitalized in Internal Medicine Wards

Recruiting now Phase 4 Last updated 16 March 2025

What this trial tests

Phase 4 trial testing Magnesium Citrate 100 MG in Hypomagnesemia in 330 participants. Currently enrolling.

Timeline

10 May 2017

Primary endpoint
1 December 2025

1 December 2026

Quick facts

Lead sponsor	Frieda Wolf
Phase	Phase 4
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	330
Start date	10 May 2017
Primary completion	1 December 2025
Estimated completion	1 December 2026
Sites	1 location across Israel

Drugs / interventions tested

Magnesium Citrate 100 MG — full drug profile →

Conditions studied

Hypomagnesemia — all drugs for Hypomagnesemia →

Sponsor

Frieda Wolf — full company profile →

Who can join

Adults 18 to 90, any sex, with Hypomagnesemia. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

compare mortality
Time frame: one year
To compare mortality between the population receiving magnesium and the population receiving standard care: ie no replacement.

Sponsor's own description

Hypomagnesemia is a common entity in the inpatient and outpatient setting. in previous retrospective study hypomagnesemic patients have higher mortality and longer hospitalization. whether hypomagnesemia is merely a marker of poor prognosis, or whether replacing it can improve outcomes is unclear. The current standard of care is to discharge these patients without workup or further treatment, even if patients had received intravenous therapy while hospitalized. The investigator wish to examine prospectively whether giving replacement therapy affects mortality, length of hospital stay and overall well-being. In order to replete intracellular levels and replete magnesium stores, magnesium should be given for several months.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hypomagnesemia

Currently open trials in the same condition.

NCT05998863 — EffCaMgCit to Prevent Mineral Metabolism and Renal Complications of Chronic PPI Therapy · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03088852 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Frieda Wolf
Last refreshed: 16 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03088852.